Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Trial Profile

Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thrombosis
  • Focus Adverse reactions
  • Acronyms RE-CIRCUIT
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 Sep 2017 According to a Boehringer Ingelheim media release, the CHMP of the EMA has issued a positive opinion for an update to the European Summary of Product Characteristics (SmPC) of Pradaxa for the treatment of patients with atrial fibrillation. The CHMP recommends to include data from this trial.If approved, the updated SmPC will state that AF patients undergoing catheter ablation who take Pradaxa 150 mg twice daily will not need to stop taking their Pradaxa medication.
    • 19 Mar 2017 Primary endpoint of incidence of Major Bleeding Events has been met, according to results published in the New England Journal of Medicine.
    • 19 Mar 2017 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top